Cargando…

Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections

Introduced in the late 1950s, polyenes represent the oldest family of antifungal drugs. The discovery of amphotericin B and its therapeutic uses is considered one of the most important scientific milestones of the twentieth century . Despite its toxic potential, it remains useful in the treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavassin, Francelise B., Baú-Carneiro, João Luiz, Vilas-Boas, Rogério R., Queiroz-Telles, Flávio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954977/
https://www.ncbi.nlm.nih.gov/pubmed/33523419
http://dx.doi.org/10.1007/s40121-020-00382-7
_version_ 1783664171083104256
author Cavassin, Francelise B.
Baú-Carneiro, João Luiz
Vilas-Boas, Rogério R.
Queiroz-Telles, Flávio
author_facet Cavassin, Francelise B.
Baú-Carneiro, João Luiz
Vilas-Boas, Rogério R.
Queiroz-Telles, Flávio
author_sort Cavassin, Francelise B.
collection PubMed
description Introduced in the late 1950s, polyenes represent the oldest family of antifungal drugs. The discovery of amphotericin B and its therapeutic uses is considered one of the most important scientific milestones of the twentieth century . Despite its toxic potential, it remains useful in the treatment of invasive fungal diseases owing to its broad spectrum of activity, low resistance rate, and excellent clinical and pharmacological action. The well-reported and defined toxicity of the conventional drug has meant that much attention has been paid to the development of new products that could minimize this effect. As a result, lipid-based formulations of amphotericin B have emerged and, even keeping the active principle in common, present distinct characteristics that may influence therapeutic results. This study presents an overview of the pharmacological properties of the different formulations for systemic use of amphotericin B available for the treatment of invasive fungal infections, highlighting the characteristics related to their chemical, pharmacokinetic structures, drug–target interactions, stability, and others, and points out the most relevant aspects for clinical practice.
format Online
Article
Text
id pubmed-7954977
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-79549772021-03-28 Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections Cavassin, Francelise B. Baú-Carneiro, João Luiz Vilas-Boas, Rogério R. Queiroz-Telles, Flávio Infect Dis Ther Review Introduced in the late 1950s, polyenes represent the oldest family of antifungal drugs. The discovery of amphotericin B and its therapeutic uses is considered one of the most important scientific milestones of the twentieth century . Despite its toxic potential, it remains useful in the treatment of invasive fungal diseases owing to its broad spectrum of activity, low resistance rate, and excellent clinical and pharmacological action. The well-reported and defined toxicity of the conventional drug has meant that much attention has been paid to the development of new products that could minimize this effect. As a result, lipid-based formulations of amphotericin B have emerged and, even keeping the active principle in common, present distinct characteristics that may influence therapeutic results. This study presents an overview of the pharmacological properties of the different formulations for systemic use of amphotericin B available for the treatment of invasive fungal infections, highlighting the characteristics related to their chemical, pharmacokinetic structures, drug–target interactions, stability, and others, and points out the most relevant aspects for clinical practice. Springer Healthcare 2021-02-01 2021-03 /pmc/articles/PMC7954977/ /pubmed/33523419 http://dx.doi.org/10.1007/s40121-020-00382-7 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Review
Cavassin, Francelise B.
Baú-Carneiro, João Luiz
Vilas-Boas, Rogério R.
Queiroz-Telles, Flávio
Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections
title Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections
title_full Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections
title_fullStr Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections
title_full_unstemmed Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections
title_short Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections
title_sort sixty years of amphotericin b: an overview of the main antifungal agent used to treat invasive fungal infections
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954977/
https://www.ncbi.nlm.nih.gov/pubmed/33523419
http://dx.doi.org/10.1007/s40121-020-00382-7
work_keys_str_mv AT cavassinfranceliseb sixtyyearsofamphotericinbanoverviewofthemainantifungalagentusedtotreatinvasivefungalinfections
AT baucarneirojoaoluiz sixtyyearsofamphotericinbanoverviewofthemainantifungalagentusedtotreatinvasivefungalinfections
AT vilasboasrogerior sixtyyearsofamphotericinbanoverviewofthemainantifungalagentusedtotreatinvasivefungalinfections
AT queiroztellesflavio sixtyyearsofamphotericinbanoverviewofthemainantifungalagentusedtotreatinvasivefungalinfections